Survival patterns among stage I and II HCC patients also differed significantly on the basis of tumor HK2 expression with a median survival time of 45 months in 63 stage I and II patients with HK2-positive tumors versus 72 months in 79 stage I and II patients with HK2-negative tumors (Log-rank p = 0.02) (Figure 2D). The gene discussed is HK2; the disease is neoplasm.